Lomerizine Prophylaxis for Pediatric Migraine: Efficacy and Predictors of Treatment Response—A Retrospective Cohort Study
Medical Sciences · 29.07.2026 · 14 (4) · 447
DOI: 10.3390/medsci14040447 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Medical Sciences, online erschienen am 29.07.2026. Verfasst von Hideki Shimomura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Hyogo, Japan. Hauptthemen laut MEDLINE: Migraine Disorders, Piperazines, Calcium Channel Blockers. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: There is limited evidence supporting the use of lomerizine, a calcium channel blocker approved for migraine prophylaxis in Japan, in children. This study evaluated the prophylactic efficacy of lomerizine in a pediatric population with migraine and identified the baseline factors independently associated with treatment response.
Methods
This single-center, retrospective cohort study enrolled 83 patients aged ≤18 years prescribed lomerizine for migraine prophylaxis. The primary outcome was headache improvement, defined as a ≥50% reduction in monthly headache days from baseline, assessed at 3–4 and 6–8 months. Multivariable logistic regression included prespecified comorbidity-based covariates: psychosocial factors, neurodevelopmental disorder, and postural orthostatic tachycardia syndrome.
Results
Headache improvement was observed in 34 of 80 (42.5%) patients at 3–4 months, and in 36 of 71 (50.7%) patients at 6–8 months. Response rates at 3–4 months and 6–8 months, respectively, were 57.7% and 67.4% among patients without psychosocial factors and 14.3% and 20.0% among those with psychosocial factors. Psychosocial factors were the only variables independently associated with a lower probability of improvement at both time points (3–4 months: adjusted odds ratio, 0.122; 95% confidence interval, 0.036–0.419; p < 0.001; 6–8 months: adjusted odds ratio, 0.137; 95% confidence interval, 0.041–0.456; p = 0.001).
Conclusions
Patients receiving lomerizine experienced clinically meaningful improvement in headache frequency, particularly those without psychosocial comorbidity. Psychosocial comorbidity was the only baseline factor independently associated with a poor treatment response, underscoring the potential importance of routine psychosocial screening and a possible benefit from concurrent psychological interventions; these findings require prospective confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, School of Medicine, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Hyogo, Japan.
- Department of Pediatrics, Kawanishi City Medical Center, 1-4-1 Hiuchi, Kawanishi City 666-0017, Hyogo, Japan.
ORCID-Profile: Hideki Shimomura, Yasuhiro Takeshima
Zitieren
APA
Shimomura, H., Tokunaga, S., Taniguchi, N., Terasaki, E., Yoshitake, S., Usami, A., Iwamoto, S., & Takeshima, Y. (2026). Lomerizine Prophylaxis for Pediatric Migraine: Efficacy and Predictors of Treatment Response—A Retrospective Cohort Study. Medical Sciences, 14(4), 447. https://doi.org/10.3390/medsci14040447
Vancouver
Shimomura H, Tokunaga S, Taniguchi N, Terasaki E, Yoshitake S, Usami A, et al. Lomerizine Prophylaxis for Pediatric Migraine: Efficacy and Predictors of Treatment Response—A Retrospective Cohort Study. Medical Sciences. 2026;14(4):447. doi:10.3390/medsci14040447
BibTeX
@article{Shimomura2026,
author = {Shimomura, Hideki and Tokunaga, Sachi and Taniguchi, Naoko and Terasaki, Eisuke and Yoshitake, Saeka and Usami, Ayuko and Iwamoto, Shintaro and Takeshima, Yasuhiro},
title = {Lomerizine Prophylaxis for Pediatric Migraine: Efficacy and Predictors of Treatment Response—A Retrospective Cohort Study},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {4},
pages = {447},
doi = {10.3390/medsci14040447}
}
EUVIMED